CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

205777Orig1s000

MICROBIOLOGY / VIROLOGY REVIEW(S)

Product Quality Microbiology Review

1/09/2014

NDA: 205777

Drug Product Name
Proprietary: Targiniq™ Tablets, controlled-release
Non-proprietary: Oxycodone hydrochloride / Naloxone hydrochloride

Review Number: 1

Dates of Submission(s) Covered by this Review

Submit	Received	Review Request	Assigned to Reviewer
9/22/2013	9/23/2013	9/25/2013	9/26/2013
12/09/2013	12/09/2013	N/A	N/A
12/24/2013	12/24/2013	N/A	N/A

Submission History (for 2nd Reviews or higher)
None

Applicant/Sponsor
Name: Purdue Pharma L.P.
Address: One Stamford Forum
201 Tresser Blvd
Stamford, CT 06901

Representative: Edward Liao, Director, US Regulatory Affairs
Telephone: 203 588-7558

Name of Reviewer: Steven P. Donald, M.S.

Conclusion: Recommended for Approval

Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: Original NDA

2. SUBMISSION PROVIDES FOR: The manufacture and marketing of an oral drug product.

3. MANUFACTURING SITE:
Purdue Pharmaceuticals L.P.
4701 Purdue Drive
Wilson, North Carolina 27893 USA

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: Tablets; Oral; 10/5, 20/10 and 40/20 mg

5. METHOD(S) OF STERILIZATION: N/A

6. PHARMACOLOGICAL CATEGORY: Analgesic

B. SUPPORTING/RELATED DOCUMENTS: None

C. REMARKS: Information requests were made on 11/26/2013 and 12/12/2013; and corresponding responses were received on 12/9/2013 and 12/24/2013.

filename: N205777r1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability - Recommended for Approval

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable – N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – The drug product is manufactured by a process (b) (4)

B. Brief Description of Microbiology Deficiencies –
No product quality microbiology deficiencies were identified based upon the information provided.

C. Assessment of Risk Due to Microbiology Deficiencies –
N/A

D. Contains Potential Precedent Decision(s)- ☐ **Yes** ☒ **No**

III. Administrative

A. Reviewer's Signature _____
Steven P. Donald, M.S.
Microbiology Reviewer

B. Endorsement Block _____
Stephen Langille, Ph.D.
Senior Microbiology Reviewer

C. CC Block
N/A

8 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEVEN P DONALD
01/13/2014

STEPHEN E LANGILLE
01/15/2014

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 205777

Applicant: Purdue Pharma L.P.
One Stamford Forum
200 Tresser Blvd
Stamford CT 06901

Letter Date: 9/22/2013

Drug Name: Oxycodone hydrochloride / Naloxone hydrochloride

NDA Type: 505 (b)(2)

Stamp Date: 9/23/2013

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		Most of the microbiology information is in Section P.2
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		Flow diagrams and notes in P.3.3; controls listed do not include those for product quality microbiology.
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?		X	USP <61> and <62> are referenced in Section P.2
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		X	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?			N/A
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	X		However, microbial limits release testing is not included.
7	Has the applicant submitted the results of analytical method verification studies?	X		However, there are none for microbiology
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?			Unknown
9	If sterile, are extended post-constitution and/or post-dilution hold times in the draft labeling supported by microbiological data?			Non-sterile

	Content Parameter	Yes	No	Comments
10	Is this NDA fileable? If not, then describe why.	X		Information in support of reduced microbial limits testing will be requested after NDA filing.

Additional Comments:
Reduced microbial limits testing is proposed.

Under justification of specifications, it is stated that microbial monitoring was performed for one batch each of the three strengths under long term storage condition in the intended commercial package. It is indicated that results showed that OXN formulations were not susceptible to microbial growth after 24-month storage and absence of objectionable organism *E. coli*. (b) (4) obtained for the three strengths of OXN tablets after storage under long term conditions for 24 months also support the low risk of microbial growth in these formulations. The applicant states that it is therefore not necessary to include microbial limits as a routine quality control test. It is not known if the applicant is talking about release testing or stability testing but is probably referring to both.

Section P.2 provides microbiological data on the referenced stability studies. (b) (4)

Steven P. Donald, M.S. — 10/15/2013
Reviewing Microbiologist — Date

Stephen Langille, Ph.D. — 10/15/2013
Microbiology Secondary Reviewer — Date

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEVEN P DONALD
10/29/2013

STEPHEN E LANGILLE
10/29/2013